DoW Breast Cancer, Era of Hope Scholar Award
Supports early-career investigators conducting innovative breast cancer research, with required consumer advocate participation and a minimum PI effort commitment.
⚑ PI must devote at least 25% effort to the award · team must include two or more breast cancer consumer advocates · must address at least one FY26 BCRP overarching challenge or justify exception · award is intended to recognize individuals/early-career leadership potential, not just projects
Unit fits — one characterization, each unit's own rules
| IPPRA | 58 good | portfolio topic: public_health; social/behavioral work is minor; funds applied research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Physical Sciences & Engineering (demo) | 55 good | technical depth: minor; funds applied research |
| Tom Love Innovation Hub | 30 weak | funds applied research; deep-tech content |
Description
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Era of Hope Scholar Award supports individuals who are early in their careers with significant potential to effect meaningful change in breast cancer. As the Intent of the FY26 BCRP Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the award’s central features include the Principal Investigator’s (PI’s) demonstrated ability to go beyond conventional thinking in their field and the innovative and meaningful contributions that they can make toward ending breast cancer. The Era of Hope Scholar Award requires exceptionally talented scientists that are among “the best and the brightest” in their field(s), with demonstrated experience forming effective partnerships and collaborations and strong potential for future leadership in breast cancer research. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.
Distinctive Features:
· The PI must commit a minimum of 25% level of time and effort during the period of performance to conduct breast cancer research under this award.
· The research team must include two or more breast cancer consumer advocates.
Apply
View on Grants.gov → CONTACT: Jamie Shortall Grant Officer <help@eBRAP.org>
Proposal brief
Proposal shell · Department of Defense (BAA-style) conventions
Legacy IPPRA LLM assessment (v2.0, for comparison)
0/100 · gpt-5.4-mini · 2026-07-06
This is a breast cancer research award aimed at early-career investigators with substantial protected effort and consumer-advocate involvement, but it is highly disease-specific biomedical research rather than the behavioral, policy, communication, or systems-focused work IPPRA leads. Even though public universities may be eligible, the opportunity does not align with IPPRA’s core portfolio or methods.
Legacy scoring history
| 2026-07-06 | 0 | gpt-5.4-mini | This is a breast cancer research award aimed at early-career investigators with substantial protected effort and consumer-advocate involvement, but it is highly disease-specific biomedical research rather than the behavioral, policy, communication, or systems-focused work IPPRA leads. Even though public universities may be eligible, the opportunity does not align with IPPRA’s core portfolio or methods. |
| 2026-07-06 | 16 | gpt-5.4-mini | This is a breast cancer research award, which is clearly within public health, but the opportunity is oriented to biomedical/clinical innovation and requires the PI to devote substantial effort to breast cancer research. IPPRA’s core strengths in survey research, risk communication, and behavioral interventions are not the main emphasis here, and the consumer-advocate requirement does not by itself create a strong fit. A public university could likely apply, but the topic is still too medically specific for more than a weak match. |